Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 109)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Povidone K30 |
Approved, Experimental, Withdrawn |
Phase 3 |
|
9003-39-8 |
6917 131751496 |
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9ci)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9ci
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-vinylpyrrolidin-2-one homopolymer
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent at 717
Agent at-717
Agrimer
Albigen a
Aldacol Q
Alphadine
Alphadines
Antaron P 804
Arufil
Betadine
Betadines
Betaisodona
Betaisodonas
Bolinan
Bolinan 40
Crospovidone
Disadine
Disadines
Dulcilarme
Dulcilarmes
Duratears free
Enterode
Enterodes
Enterodez
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
Huntington laboratories brand OF povidone iodine
Huntington laboratories brand OF povidone-iodine
Hypotear
Hypotears
Isodine
Isodines
K 115 (Polyamide)
K 25
K 25 (Polymer)
K 30
K 30 (Polymer)
K 60
K 60 (Polymer)
K115 (Polyamide)
K25 (Polymer)
K30 (Polymer)
K60 (Polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Lacophtal
Lacri-stulln
Lagrifilm
Liquifilm lagrimas
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
N- Vinyl pyrrolidone
Neocompensan
Nutrivisc
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Oculotect
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
Pharmadine
Pharmadines
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone K29/32
Plasdone K29-32
|
Plasdone no. 4
Plasdone XL
Plasmosan
Polividone
Polvidone
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper's polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar H
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidon
Polyvidons
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone iodine
Polyvinylpyrrolidone iodines
Polyvinylpyrrolidone K 30
Polyvinylpyrrolidone K-29/32
Polyvinylpyrrolidone K30
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidona
Povidone
Povidone iodine
Povidone K29/32
Povidone K29-32
Povidone(usan)
Povidone, ban, usan
Povidone, unspecified
Povidone-iodine
Povidone-iodines
Povidonum
Protagen
Protagens
Protagent
Providine
Providines
PVP 1
PVP 2
PVP 3
PVP 4
PVP 40
PVP 5
PVP 6
PVP 7
PVP Iodine
PVP K 3
PVP K30
PVP K-30
PVP10_SIAL
PVP40_SIAL
PVP-I
PVP-Iodine
PVP-Iodines
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131
Tolpovidone I-131
Toxobin
Unifluid
Unspecified povidone
Vidirakt S mit PVP
Vidisic PVP ophtiole
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
Wet-comod
|
|
2 |
|
Metformin |
Approved |
Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
3 |
|
Titanium dioxide |
Approved |
Phase 3 |
|
13463-67-7 |
|
Synonyms:
dióxido de titanio
óxido de titanio(4)
|
|
|
4 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
5 |
|
Etoposide |
Approved |
Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
6 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
7 |
|
Vincristine |
Approved, Investigational |
Phase 3 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-OXOVINCALEUKOBLASTIN
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
22-oxovincaleukoblastine|kyocristine|leurocristine sulfate|NSC-67574|Oncovin®
37231
Cellcristin
Citomid
Farmistin
Indole alkaloid
KYOCRISTINE
LCR
Leucristine
Leurocristine
LEUROCRISTINE SULFATE
LILLY-37231
Marqibo
MARQIBO KIT
NSC-67574
Onco TCS
Oncovin
Oncovine
Onkocristin
PFS, Vincasar
|
Sulfate, vincristine
Tecnocris
VCR
VIN
Vincasar
Vincasar PFS
VINCREX
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
VINCRISTINE
Vincristine sulfate
VINCRISTINE SULFATE PFS
VINCRISTINUM
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
|
|
8 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 3 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
9 |
|
Methotrexate |
Approved |
Phase 3 |
|
1959-05-2, 59-05-2 |
4112 126941 |
Synonyms:
[<sup>3</sup>H]-methotrexate
2-[(4-{[(4-amino-2-imino-2,3-dihydropteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioate
4-Amino-10-methylfolate
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-Amino-N(10)-methylpteroylglutamic acid
ABITREXATE
Abitrexate®|amethopterin|Nordimet®|Rasuvo®
Amethopterin
Amethopterine
Antifolan
Arbitrexate
CL-14377
Dicesium salt methotrexate
EBETREX
EMT-25299
Emtexate
EMTEXATE HIGH-POT
EMTEXATE PF
Emtexic acid
FOLEX
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
MAXTREX
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
Méthotrexate
Methotrexate hydrate
|
Methotrexate sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
METOJECT
Metotrexato
Mexate
MEXATE-AQ
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
NSC-740
Otrexup
OTREXUP PFS
R-9985
RASUVO
Rheumatrex
R-METHOTREXATE
Sodium, methotrexate
TCMDC-123832
TCMDC-125488
TCMDC-125858
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexate
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexic acid
Trexall
Xatmep
ZLATAL
|
|
10 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
11 |
|
Lomustine |
Approved, Investigational |
Phase 3 |
|
13010-47-4 |
3950 |
Synonyms:
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
Belustine
Bristol myers squibb brand OF lomustine
Bristol-myers squibb brand OF lomustine
CCNU
CCN-U
Cecenu
CeeNU
Chloroethylcyclohexylnitrosourea
CINU
|
Cyclohexyl chloroethyl nitrosourea
Gleostine
Lomustina
LOMUSTINE
Lomustine medac brand
Lomustinum
Medac brand OF lomustine
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NSC-79037
Rhône poulenc rorer brand OF lomustine
Rhône-poulenc rorer brand OF lomustine
|
|
12 |
|
Thiotepa |
Approved, Investigational |
Phase 3 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
NSC-6396
Rethio
Tepadina
Tepadina®|Thioplex®
Tespa
Tespamin
Thio tepa
|
Thiophosphamide
Thioplex
Thio-tepa
THIOTEPA
THIOTEPA 或 THIOTEPA
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
13 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
14 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
15 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
16 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
17 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
18 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
19 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
20 |
|
Folate |
|
Phase 3 |
|
|
|
21 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
22 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
23 |
|
Etoposide phosphate |
|
Phase 3 |
|
|
16760419 |
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
24 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
25 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
26 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
27 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
28 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
29 |
|
Vitamins |
|
Phase 3 |
|
|
|
30 |
|
Trace Elements |
|
Phase 3 |
|
|
|
31 |
|
Antidotes |
|
Phase 3 |
|
|
|
32 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
33 |
|
Micronutrients |
|
Phase 3 |
|
|
|
34 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
35 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
36 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
37 |
|
Octreotide |
Approved, Investigational |
Phase 2 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
38 |
|
Somatostatin |
Approved, Investigational |
Phase 2 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
39 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
40 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
41 |
|
Lapatinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
42 |
|
Picropodophyllin |
Approved, Investigational |
Phase 2 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
43 |
|
Topotecan |
Approved, Investigational |
Phase 2 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
44 |
|
D-Phenylalanine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
63-91-2, 673-06-3 |
6140 71567 |
Synonyms:
(-)-beta-Phenylalanine
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-AMINO-3-PHENYLPROPIONIC ACID
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-ALPHA-AMINO-BETA-PHENYLPROPIONIC ACID
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
3-PHENYL-L-ALANINE
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
a-Amino-b-phenylpropionate
a-Amino-b-phenylpropionic acid
alpha-Amino-beta-phenylpropionate
alpha-Amino-beta-phenylpropionic acid
alpha-Aminohydrocinnamate
|
alpha-Aminohydrocinnamic acid
beta-Phenylalanine
beta-Phenyl-alpha-alanine
BETA-PHENYL-L-ALANINE
b-Phenyl-L-alanine
D-(+)-phenylalanine
DL-Phenylalanine
Endorphenyl
F
FEMA NO. 3585
Fenilalanina
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-Isomer phenylalanine
L-PHE
L-Phenylalanine
NSC-79477
PHE
Phenylalamine
Phenylalanin
Phenylalanine
Phenyl-alanine
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Tetrahydrofolate
THF
Α-amino-β-phenylpropionate
Α-amino-β-phenylpropionic acid
Î’-PHENYL-L-ALANINE
|
|
45 |
|
Camptothecin |
Experimental |
Phase 2 |
|
7689-03-4 |
24360 |
Synonyms:
(+)-camptothecin
(+)-camptothecine
(S)-(+)-camptothecin
(S)-CAMPTOTHECIN
20(S)-CAMPTOTHECIN
20(S)-camptothecine
|
21,22-Secocamptothecin-21-oic acid lactone
CAMPTOTHECIN
Camptothecine
CPT
D-camptothecin
NSC-94600
|
|
46 |
|
Tipifarnib |
Investigational |
Phase 2 |
|
192185-72-1 |
159324 |
Synonyms:
R-11577
R-115777
R-115777|R115777
|
|
|
47 |
|
Genistein |
Investigational |
Phase 2 |
|
446-72-0 |
5280961 |
Synonyms:
4',5, 7-Trihydroxyisoflavone
4,5,7-Trihydroxy iso-flavone
4',5,7-Trihydroxyisoflavone
4',5,7-Trihydroxy-isoflavone
5,7,4'-Trihydroxyisoflavone
5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
FW-635I-2
Genestein
GENISTEIN
|
Genistein 85% HPLC
Genisteol
Genisterin
NPI-031L
NSC-36586
Prunetol
SIPI-807-1
Sophoricol
|
|
48 |
|
Radiopharmaceuticals |
|
Phase 2 |
|
|
|
49 |
|
Edotreotide |
|
Phase 2 |
|
|
23724894 |
Synonyms:
2-(4-{[(1-{[10-(4-aminobutyl)-4-[(1,3-dihydroxybutan-2-yl)-C-hydroxycarbonimidoyl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}-2-phenylethyl)-C-hydroxycarbonimidoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetate
|
DOTA-Tyr<sup>3</sup>-octreotide|DOTA<sup>0</sup>-Phe<sup>1</sup>-Tyr<sup>3</sup>-octreotide|Ga-DOTA-TOC|Ga-DOTATOC|SMT487|SomaKit TOC®
|
|
50 |
|
Indium-111-octreotide |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 53)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children's Oncology Group Phase III Study |
Completed |
NCT00006461 |
Phase 3 |
cisplatin;cyclophosphamide;vincristine sulfate;etoposide |
2 |
Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Medulloblastoma Patients |
Recruiting |
NCT05230758 |
Phase 3 |
Metformin hydrochloride (HCl) 500mg tablet;Placebo |
3 |
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial |
Active, not recruiting |
NCT00085735 |
Phase 3 |
Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate |
4 |
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate |
Active, not recruiting |
NCT00336024 |
Phase 3 |
etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate |
5 |
Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer |
Terminated |
NCT01987596 |
Phase 3 |
|
6 |
Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors |
Completed |
NCT01869725 |
Phase 2 |
gallium Ga 68-edotreotide |
7 |
Phase II Study of Bevacizumab Plus Irinotecan (Camptosarâ„¢) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
Completed |
NCT00381797 |
Phase 2 |
Irinotecan Hydrochloride |
8 |
Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma |
Completed |
NCT00095940 |
Phase 1, Phase 2 |
lapatinib ditosylate |
9 |
A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma |
Completed |
NCT00070525 |
Phase 2 |
tipifarnib |
10 |
A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies |
Completed |
NCT00005811 |
Phase 2 |
topotecan hydrochloride |
11 |
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors |
Completed |
NCT00004078 |
Phase 2 |
irinotecan hydrochloride |
12 |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma |
Completed |
NCT01239316 |
Phase 2 |
Vismodegib |
13 |
Phase IB Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AloCELYVIR (Mesenchymal Allogenic Cells + ICOVIR-5) in Children, Adolescent and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Relapse/Progression in Monotherapy |
Recruiting |
NCT04758533 |
Phase 1, Phase 2 |
|
14 |
PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma |
Recruiting |
NCT03904862 |
Phase 1, Phase 2 |
CX 4945 |
15 |
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age |
Active, not recruiting |
NCT02017964 |
Phase 2 |
Carboplatin;Cyclophosphamide;Etoposide;Methotrexate;Vincristine Sulfate |
16 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations |
Suspended |
NCT03210714 |
Phase 2 |
Erdafitinib |
17 |
A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors |
Terminated |
NCT02684071 |
Phase 2 |
Intra thecal methotrexate;topotecan;cyclophosphamide |
18 |
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy |
Terminated |
NCT02624388 |
Phase 2 |
Genistein;Placebo |
19 |
A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma |
Terminated |
NCT04167618 |
Phase 1, Phase 2 |
177Lu-DTPA-omburtamab |
20 |
Phase I Study of Intraventricular Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol |
Completed |
NCT02271711 |
Phase 1 |
|
21 |
A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 |
Completed |
NCT00822458 |
Phase 1 |
vismodegib |
22 |
A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS |
Completed |
NCT00012181 |
Phase 1 |
alvocidib |
23 |
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas |
Completed |
NCT00994500 |
Phase 1 |
vorinostat;bortezomib |
24 |
A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors |
Completed |
NCT00077454 |
Phase 1 |
erlotinib hydrochloride;temozolomide |
25 |
A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas |
Completed |
NCT00101270 |
Phase 1 |
irinotecan hydrochloride;oxaliplatin |
26 |
Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors |
Completed |
NCT00052780 |
Phase 1 |
O6-benzylguanine;temozolomide |
27 |
A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors |
Completed |
NCT00100880 |
Phase 1 |
lenalidomide |
28 |
Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors |
Completed |
NCT00063973 |
Phase 1 |
cilengitide |
29 |
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors |
Completed |
NCT01076530 |
Phase 1 |
vorinostat;temozolomide |
30 |
A Phase 1 Study of SAHA (NSC# 701852) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors |
Completed |
NCT00217412 |
Phase 1 |
vorinostat;isotretinoin |
31 |
A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS |
Completed |
NCT00363272 |
Phase 1 |
ispinesib |
32 |
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors |
Completed |
NCT00326664 |
Phase 1 |
Cediranib Maleate |
33 |
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
Completed |
NCT00946335 |
Phase 1 |
veliparib;temozolomide |
34 |
A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS |
Completed |
NCT00053963 |
Phase 1 |
romidepsin |
35 |
A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults With Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT) |
Recruiting |
NCT02962167 |
Phase 1 |
|
36 |
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors |
Recruiting |
NCT04185038 |
Phase 1 |
|
37 |
Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors |
Active, not recruiting |
NCT00638898 |
Phase 1 |
busulfan;melphalan;topotecan hydrochloride |
38 |
Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors |
Active, not recruiting |
NCT02444546 |
Phase 1 |
|
39 |
Phase I Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric and Young Adult Patients Affected by Relapsed/Refractory Central Nervous System Tumors |
Not yet recruiting |
NCT05298995 |
Phase 1 |
|
40 |
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors |
Terminated |
NCT02255461 |
Phase 1 |
palbociclib isethionate |
41 |
A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA |
Terminated |
NCT01088763 |
Phase 1 |
gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone |
42 |
A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma |
Withdrawn |
NCT01697514 |
Phase 1 |
LY2940680 |
43 |
Multi-center Retrospective Study on Clinical Features and Molecular Subgroups of Children and Adolescents With Medulloblastoma in China |
Unknown status |
NCT03288168 |
|
|
44 |
Child's Study of the Distant Impact of Posterior Fossa Injury on Motor Skills, Language, Cognitive Functioning, and Social Cognition - a Combination of Clinical Assessments and Brain Imaging |
Unknown status |
NCT04174820 |
|
|
45 |
Metabolomic Analysis of Body Fluid of Medulloblastoma in Children Based on New Mass Spectrometry and Its Application in Clinical Diagnosis and Recurrence Monitoring |
Unknown status |
NCT04065204 |
|
|
46 |
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens |
Completed |
NCT00919750 |
|
|
47 |
Efficacy Of Dual Task Training On Children With Ataxia After Medulloblastoma Resection |
Completed |
NCT04860934 |
|
|
48 |
Impact of Physical Activity on Postural Stability and Coordination in Children With Posterior Fossa Tumor |
Completed |
NCT04528316 |
|
|
49 |
Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, Central Nervous System (CNS)- Primitive Neuroectodermal Tumour (PNET), or Ependymoma |
Completed |
NCT02238899 |
|
|
50 |
Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma |
Completed |
NCT02747576 |
|
|
|